Seragon Pharmaceuticals

9 articles with Seragon Pharmaceuticals

• 

  A New $550 Million Life Sciences Venture Capital Fund is in Town

  6/3/2021

  venBio Global Strategic Fund IV will invest primarily in drug companies focused on developing therapies for unmet medical needs.

• Seragon Announces GenomeScore™, the First AI Platform to Measure Rate of Aging and Physiological Changes

  8/4/2020

  The novel algorithms combine epigenetic and transcriptome analyses to reveal how a person ages in different areas, and opens a door to personalized medicine in the future

• Seragon Pharmaceuticals announces GenomeScore™, an AI platform to predict speed of aging and physiological changes

  7/22/2020

  Seragon Pharmaceuticals, Inc., a southern California biopharmaceutical company, announces GenomeScore™ platform, a neural network-trained algorithm combining epigenetic and transcriptome analysis to predict individuals' aging speed and assessing aspects of physiological functions.

• 

  Metacrine Closes $65 Million Series C Round

  6/6/2018

  Metracrine, based in San Diego, completed a Series C financing round worth $65 million.

• Stealth SoCal Startup Metacrine Eyes $33 Million and Talent-Cash From Seragon Alums?

  4/22/2015

• Seragon Pharmaceuticals Announces Closing Of Its Acquisition By Genentech

  8/28/2014

• Genentech To Pay Up To $1.7 Billion For San Diego Biotech Firm Seragon Pharmaceuticals

  7/7/2014

• Seragon Pharmaceuticals Appoints Debasish Roychowdhury, M.D. To Its Clinical And Scientific Advisory Board And As Acting Chief Medical Officer

  4/3/2014

• Startup Seragon Pharmaceuticals Lands $30 Million in Series A Financing

  10/16/2013